Two of the six patients with PD-L1 CPS ≤1 in the experimental cohort achieved pCR, and the rate of pCR in the experimental group was 36.4%; it might be even higher if we could avoid the influence of COVID-19. This evidence concerns the gene CD274 and COVID-19.